S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Verve Therapeutics (VERV) Earnings Date, Estimates & Call Transcripts

$13.45
+0.13 (+0.98%)
(As of 02/23/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

VERV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VERV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Verve Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.74)($0.74)($0.74)
Q2 20241($0.74)($0.74)($0.74)
Q3 20241($0.79)($0.79)($0.79)
Q4 20241($0.80)($0.80)($0.80)
FY 20244($3.07)($3.07)($3.07)
Q1 20251($0.82)($0.82)($0.82)
Q2 20251($0.82)($0.82)($0.82)
Q3 20251($0.83)($0.83)($0.83)

VERV Earnings Date and Information

Verve Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off prior year's report dates.

Verve Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/7/2024
Estimated)
------- 
11/7/2023Q3 2023($0.90)($0.72)+$0.18($0.72)$0.96 million$3.10 million    
8/10/2023Q2 2023($0.90)($0.87)+$0.03($0.87)$0.67 million$2.10 million
5/15/2023Q1 2023($0.77)($0.84)($0.07)($0.84)$1.00 million$1.40 million
3/2/2023Q4 2022($0.76)($0.67)+$0.09($0.67)$1.50 million$1.01 million
11/7/2022Q3 2022($0.75)($0.79)($0.04)($0.79)$5.00 million$0.93 million
8/9/2022Q2 2022($0.63)($0.84)($0.21)($0.84)--
5/10/2022Q1 2022($0.63)($0.62)+$0.01($0.62)--
3/14/2022Q4 2021($0.54)($0.65)($0.11)($0.65)--
11/10/2021Q3 2021($0.45)($0.47)($0.02)($0.47)--
8/12/2021Q2 2021($0.53)($2.13)($1.60)$2.40--












Verve Therapeutics Earnings - Frequently Asked Questions

When is Verve Therapeutics's earnings date?

Verve Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off last year's report dates. Learn more on VERV's earnings history.

How much revenue does Verve Therapeutics generate each year?

Verve Therapeutics (NASDAQ:VERV) has a recorded annual revenue of $1.94 million.

How much profit does Verve Therapeutics generate each year?

Verve Therapeutics (NASDAQ:VERV) has a recorded net income of -$157.39 million. VERV has generated -$3.10 earnings per share over the last four quarters.

What is Verve Therapeutics's EPS forecast for next year?

Verve Therapeutics's earnings are expected to decrease from ($3.29) per share to ($3.32) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:VERV) was last updated on 2/24/2024 by MarketBeat.com Staff